Indianapolis Business Journal

OCTOBER 22-28, 2012

This week, read about Indianapolis Symphony Orchestra's ambitious fundraising goal and find out why state securities regulators are going after the investment firm that raised $5 million for homebuilder Paul Estridge Jr. And in Focus, discover the connection between tech entrepreneurs and health care providers.

Front PageBack to Top

Airport’s ground game fueling tensions

The Indianapolis Airport Authority’s aggressive effort to stop an Ohio firm from building a parking facility beyond airport boundaries has neighbors worrying the municipality will unleash its lawyers on virtually any nearby business deemed a threat to airport revenue.

Read More

Top StoriesBack to Top

FocusBack to Top

OpinionBack to Top

Question Rockport

One is left to wonder why Bill Styring [Oct. 15 Forefront] and others like him were so darned slow to engage in this issue.

Read More

Sports, arts not rivals

Bill Benner’s [Oct. 15] column on arts versus sports drives home the point of the misguided view that the arts and sports are equal rivals! This column should have appeared on your front page!

Read More

Might leave the state

[Hetrick’s Oct. 8 column] was spot on. I tend Democrat but have been voting for Richard Lugar since I could vote in 1972.

Read More

Disheartening response

Thank you for the [Oct. 8 Morris column] on the Senate race. Some important issues seem to be swept under the rug in this important race.

Read More

Obesity battle can be won

The shocking news about obesity keeps on coming. As IBJ reported in its Oct. 8 editorial, “Residents’ health a weighty issue,” more than half of Hoosiers will be obese by 2030, costing us billions of dollars in health care and lost productivity.

Read More

In BriefBack to Top

Can Lilly capitalize on Alzheimer’s breakthrough?

Eli Lilly and Co. has apparently made major medical history by being the first to develop a drug that alters the course of Alzheimer’s disease. But whether Lilly can be the first to make major money from a disease-altering Alzheimer’s drug is still in doubt.

Read More